Advancements in Treatment Approaches for AML

Dear Colleagues,

We are excited to announce the call for contributions to this Special Issue on "Advancements in Treatment Approaches for AML", focusing on the advancements in diagnosis, prognostication, and treatment strategies for acute myeloid leukemia (AML).

This Special Issue aims to explore novel diagnostic and treatment strategies throughout the entire spectrum of AML treatment across various settings. We invite you to share your valuable research and insights in the form of original research articles and reviews. Through the course of collaborating with experts, we aim to ensure the success of this endeavor.

Potential research areas for this Special Issue include, but are not limited to, the following:

- Molecular pathogenesis and biological insights into AML;

- Diagnostic algorithms and advancements;

- Clinical trials exploring innovative therapeutic approaches;

- Novel therapeutic targets and immunotherapy in AML;

- Guideline recommendations for diagnosis and management, considering the era of novel drugs;

- Novel strategies in allogeneic hematopoietic stem cell transplantation (HSCT).

All submitted articles will undergo a rigorous peer review process to ensure the highest scientific quality and relevance to this field. We encourage contributions from researchers, clinicians, and experts in the fields of breast cancer research and oncology.

Your contributions to this Special Issue will contribute to the collective understanding and progress in the field of AML treatment. We look forward to receiving your submissions.

Should you have any questions, require further information, or need any assistance, please do not hesitate to reach out to us. We are here to support and facilitate your participation in this Special Issue.

Thank you for your attention to this matter, and we look forward to receiving your valuable submissions.

Dr. Semra Aydin
Dr. Raheel Iftikhar
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• AML treatment
• allogeneic HSCT
• novel targeted therapeutic agents
• diagnostic
• treatment strategies